CARDIOGEN

Tissue Repair & HealingResearch Only

The evidence summary appears confused, mixing this peptide with CardioGen-82 imaging technology rather than the actual Cardiogen bioregulator peptide. True research data on this specific tripeptide remains limited and largely preliminary.

Primarily studied by researchers investigating bioregulatory peptides for age-related cardiovascular decline and cardiac tissue regeneration.

FDA Status

Research Only

Since Feb 2026

Evidence

Moderate

Studies

12 total, 2 human

What is CARDIOGEN?

This tripeptide (Ala-Glu-Asp) belongs to the Khavinson bioregulator family, a series of short peptides developed by Russian researcher Vladimir Khavinson for tissue-specific regenerative applications. Cardiogen specifically targets cardiac tissue function and has been investigated primarily in the context of age-related cardiovascular decline. Research teams studying bioregulatory peptides and cardiac aging represent the main groups examining this compound.

The peptide appears to function by binding to specific DNA sequences in heart muscle cells, potentially influencing which genes get turned on or off in cardiomyocytes. This epigenetic modulation could affect the production of proteins essential for heart muscle contraction and cellular repair processes. Think of it as a molecular switch that might help aging heart cells remember how to function more like younger, healthier cells.

What the Research Shows

The current evidence summary incorrectly references cardiac imaging studies rather than bioregulator peptide research, indicating a significant data quality issue that makes proper assessment impossible.

Available evidence for CARDIOGEN consists of 12 studies (10 human studies, 0 randomized controlled trials) primarily focused on CardioGen-82 rubidium generator technology and its clinical applications in cardiac imaging. Key findings include documentation of Rb-82 production efficiency comparisons with alternative systems, a registry of 809 cardiomyopathy and ion channel disease patients showing mortality and morbidity rates consistent with published literature, and validation of dosing accuracy maintenance without recalibration for doses 26 mCi or greater when initially calibrated to 30 mCi.